Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (operating subsidiary: CytoSorbents, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Status: Development stage company; no commercial revenue generated to date.
Primary Activity: Research, development, and commercialization of the CytoSorb blood purification device, currently focused on a clinical trial in Europe for the treatment of sepsis.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
Balance Sheet June 30, 2009 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Total Expenses | $1,618,892 | $1,457,911 | N/A |
| Net Loss | $(1,612,096) | $(1,501,727) | N/A |
| Accumulated Deficit | N/A | N/A | $(77,413,342) |
| Cash and Cash Equivalents | N/A | N/A | $1,423,608 |
| Current Liabilities | N/A | N/A | $919,813 |
| Notes Payable | N/A | N/A | $50,000 |
| Net Cash Used in Operations | $(1,511,646) | $(887,570) | N/A |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2009, increased by approximately $110,000 compared to the same period in 2008, driven primarily by higher Research and Development (R&D) expenses ($1,069,931 vs. $782,563) and General and Administrative expenses.
- Cash Burn: Cash and cash equivalents decreased by approximately $1.33 million from $2,749,208 at December 31, 2008, to $1,423,608 at June 30, 2009.
- Capital Structure Changes: Significant non-cash activity occurred, including the conversion of Series A and Series B Preferred Stock into Common Stock (16,256,910 common shares issued) and the issuance of preferred stock as dividends.
- Going Concern: The filing reiterates substantial doubt about the company's ability to continue as a going concern due to the accumulated deficit and reliance on future financing.
Outlook, Risks, and Management Commentary
- Clinical Trial Progress: The company is conducting a clinical study in Europe (Germany) for the CytoSorb device. As of August 2009, 29 patients had been enrolled, with 11 hospital sites participating. Management anticipates enrolling approximately 80 patients total.
- Regulatory Strategy: The company is targeting CE Mark approval in Europe for 2010, believing the path is faster than FDA approval. A protocol revision was approved to optimize data collection for the primary endpoint (cytokine reduction).
- Liquidity Risk: Management estimates current cash reserves are sufficient to fund operations only into the fourth quarter of 2009. Additional funding is required to complete clinical studies and commercialize products. There is no assurance that financing will be available.
- Legal Proceedings: A trademark dispute with Alkermes, Inc. regarding the name "MedaSorb" was settled in 2008. The operating subsidiary was renamed CytoSorbents, Inc., while the parent company retains the MedaSorb name.
- Contingencies: The company has royalty agreements (3% on gross revenues) and license agreements (2.5% to 5% royalties) that will trigger upon commercial sales, though no liability has been accrued as no revenue has been generated.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure financing before the end of Q4 2009 to avoid operational suspension.
- Clinical Enrollment: Monitor the rate of patient enrollment in the European clinical trial against the target of 80 patients.
- Regulatory Timeline: Track the submission and approval status of the CE Mark application for 2010.
- Dilution Risk: Review the impact of outstanding warrants (approx. 3.9 million common shares) and convertible preferred stock on future equity dilution.
- Going Concern Status: Assess the likelihood of continued operations given the $77.4 million accumulated deficit and lack of revenue.